Vaccine From Asian Bird Flu Strains Shows Effective In Trials
This article was originally published in PharmAsia News
Executive Summary
A U.S. drug maker using Vietnam, Hong Kong and Indonesian bird-flu viruses has developed a vaccine that has survived Phase II trials. Baxter International's Celvapan showed in second-stage trials to be capable of protecting 76 percent of the participants from the Vietnam and Hong Kong strains and 45 percent of them from the Indonesian strain. The success of the vaccine so far is seen as promising for a faster way of developing a vaccine to avoid a global pandemic of the H5N1 avian influenza. Baxter said its vaccine-making method could allow production of a new vaccine within as little as 12 weeks. (Click here for more